WO2018026779A1 - Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations - Google Patents

Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations Download PDF

Info

Publication number
WO2018026779A1
WO2018026779A1 PCT/US2017/044838 US2017044838W WO2018026779A1 WO 2018026779 A1 WO2018026779 A1 WO 2018026779A1 US 2017044838 W US2017044838 W US 2017044838W WO 2018026779 A1 WO2018026779 A1 WO 2018026779A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
group
occurrence
independently selected
Prior art date
Application number
PCT/US2017/044838
Other languages
English (en)
Inventor
M. Amin Khan
Original Assignee
Aptinyx Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16/321,905 priority Critical patent/US11299495B2/en
Priority to JP2019505213A priority patent/JP2019527233A/ja
Priority to SG11201900443VA priority patent/SG11201900443VA/en
Priority to EA201990424A priority patent/EA201990424A1/ru
Priority to BR112019001768A priority patent/BR112019001768A2/pt
Priority to CN201780048099.4A priority patent/CN109937204B/zh
Priority to KR1020197005666A priority patent/KR102465758B1/ko
Application filed by Aptinyx Inc. filed Critical Aptinyx Inc.
Priority to MX2019001319A priority patent/MX2019001319A/es
Priority to AU2017306152A priority patent/AU2017306152A1/en
Priority to CA3031537A priority patent/CA3031537A1/fr
Priority to EP17751544.2A priority patent/EP3490992B1/fr
Publication of WO2018026779A1 publication Critical patent/WO2018026779A1/fr
Priority to PH12019500202A priority patent/PH12019500202A1/en
Priority to IL264514A priority patent/IL264514B/en
Priority to CONC2019/0000945A priority patent/CO2019000945A2/es
Priority to US17/401,653 priority patent/US11530223B2/en
Priority to AU2021240150A priority patent/AU2021240150A1/en
Priority to JP2022092387A priority patent/JP7448766B2/ja
Priority to US18/055,095 priority patent/US20230312591A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • R 7 is independently selected from the group consisting of H, -Ci-C 6 alkyl, -S(0) w -Ci_ C 3 alkyl, and halogen;
  • compounds described herein bind to NMD A receptors expressing certain NR2 subtypes. In some aspects, the compounds described herein bind to one NR2 subtype and not another.
  • Ci-C 6 alkyl group examples include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, icri-butyl, isopentyl, and neopentyl.
  • C1-C4 alkyl refers to a straight-chain or branched saturated hydrocarbon containing 1-4 carbon atoms.
  • Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2- methyl-2-propyl, 2-methyl-l-butyl, 3 -methyl- 1 -butyl, 3-methyl-2-butyl, 2,2-dimethyl-l-propyl, 2-methyl-l -pentyl, 3-methyl-l -pentyl, 4-methyl-l -pentyl, 2-methyl-2-pentyl, 3-methyl-2- pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl.
  • cyano refers to the radical -CN.
  • cycloalkyl refers to a monocyclic saturated or partially unsaturated hydrocarbon ring (carbocyclic) system, for example, where each ring is either completely saturated or contains one or more units of unsaturation, but where no ring is aromatic.
  • a cycloalkyl can have 3-6 or 4-6 carbon atoms in its ring system, referred to herein as C3-C 6 cycloalkyl or C4-C 6 cycloalkyl, respectively.
  • Exemplary cycloalkyl groups include, but are not limited to, cyclohexyl, cyclohexenyl, cyclopentyl, cyclopentenyl, cyclobutyl, and cyclopropyl.
  • the disclosure also embraces isotopically-labeled compounds which are identical to those compounds recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H ("D"), 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively.
  • a compound described herein can have one or more H atoms replaced with deuterium.
  • compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that can be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfon
  • the compounds disclosed herein can exist in a solvated form as well as an unsolvated form with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms.
  • pharmaceutically acceptable solvents such as water, ethanol, and the like
  • R 6 represents one or two optional substitutions each on one or more available ring carbons, and is independently selected for each occurrence from the group consisting of Ci-C 6 alkyl, -S(0) w -Ci_C 3 alkyl, -NR a R b and halogen;
  • w 0, 1, or 2;
  • R 3 is selected from the group consisting of H, phenyl, Ci-C 6 alkyl, -C(0)R 31 and - C(0)OR 32 ;
  • R 31 and R 32 are each independently H, Ci-Cealkyl, -C 3 -Cecycloalkyl, and phenyl;
  • R a and R b are each independently for each occurrence selected from the group consisting of H, phenyl, and Ci-C 3 alkyl, or R a and R b taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;
  • R 1 can be C(0)-Ci-C 6 alkyl, where C(0)-Ci-C 6 alkyl can be represented by:
  • R 3 can be H. In certain embodiments, R 3 can be selected from the group consisting of
  • EXAMPLE 4 Following the above procedures, the following compounds were or are prepared. It should be appreciated that the compound in the first column is a different stereoisomer, for example, a different enantiomer and/or different diastereomer, from the compound in the second column.
  • Sprague Dawley rats were dosed intravenously using a normal saline formulation containing 2 mg/kg of the compounds identified in the below table (except for the first four compounds that were delivered in 5 % NMP, 5% Solutol ® HS and 90 % normal saline formulation).
  • the table below summarizes the results of the IV pharmacokinetics.

Abstract

L'invention concerne des composés ayant une puissance dans la modulation de l'activité des récepteurs NMDA. De tels composés peuvent être utilisés dans le traitement d'états tels que la dépression et les troubles associés. L'invention concerne également des formulations disponibles par voie orale et d'autres formes d'administration pharmaceutiquement acceptables des composés, y compris des formulations intraveineuses.
PCT/US2017/044838 2016-08-01 2017-08-01 Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations WO2018026779A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2019505213A JP2019527233A (ja) 2016-08-01 2017-08-01 スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
SG11201900443VA SG11201900443VA (en) 2016-08-01 2017-08-01 Spiro-lactam nmda receptor modulators and uses thereof
EA201990424A EA201990424A1 (ru) 2016-08-01 2017-08-01 Спиролактамовые модуляторы nmda-рецептора и их применение
BR112019001768A BR112019001768A2 (pt) 2016-08-01 2017-08-01 moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
CN201780048099.4A CN109937204B (zh) 2016-08-01 2017-08-01 螺-内酰胺nmda受体调节剂及其用途
KR1020197005666A KR102465758B1 (ko) 2016-08-01 2017-08-01 스피로-락탐 nmda 수용체 조정제 및 그의 용도
AU2017306152A AU2017306152A1 (en) 2016-08-01 2017-08-01 Spiro-lactam NMDA receptor modulators and uses thereof
MX2019001319A MX2019001319A (es) 2016-08-01 2017-08-01 Moduladores del receptor nmda espiro-lactam y uso de los mismos.
EP17751544.2A EP3490992B1 (fr) 2016-08-01 2017-08-01 Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations
US16/321,905 US11299495B2 (en) 2016-08-01 2017-08-01 Spiro-lactam NMDA receptor modulators and uses thereof
CA3031537A CA3031537A1 (fr) 2016-08-01 2017-08-01 Modulateurs spiro-lactames des recepteurs nmda et leurs utilisations
IL264514A IL264514B (en) 2016-08-01 2019-01-28 Spiro-lactam nmda receptor modulators and their uses
PH12019500202A PH12019500202A1 (en) 2016-08-01 2019-01-28 Spiro-lactam nmda receptor modulators and uses thereof
CONC2019/0000945A CO2019000945A2 (es) 2016-08-01 2019-01-30 Moduladores del receptor nmda espiro-lactam y uso de los mismos
US17/401,653 US11530223B2 (en) 2016-08-01 2021-08-13 Spiro-lactam NMDA receptor modulators and uses thereof
AU2021240150A AU2021240150A1 (en) 2016-08-01 2021-09-28 Spiro-lactam NMDA receptor modulators and uses thereof
JP2022092387A JP7448766B2 (ja) 2016-08-01 2022-06-07 スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
US18/055,095 US20230312591A1 (en) 2016-08-01 2022-11-14 Spiro-lactam nmda receptor modulators and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662369453P 2016-08-01 2016-08-01
US62/369,453 2016-08-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/321,905 A-371-Of-International US11299495B2 (en) 2016-08-01 2017-08-01 Spiro-lactam NMDA receptor modulators and uses thereof
US17/401,653 Division US11530223B2 (en) 2016-08-01 2021-08-13 Spiro-lactam NMDA receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
WO2018026779A1 true WO2018026779A1 (fr) 2018-02-08

Family

ID=59582038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/044838 WO2018026779A1 (fr) 2016-08-01 2017-08-01 Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations

Country Status (17)

Country Link
US (3) US11299495B2 (fr)
EP (1) EP3490992B1 (fr)
JP (2) JP2019527233A (fr)
KR (1) KR102465758B1 (fr)
CN (1) CN109937204B (fr)
AU (2) AU2017306152A1 (fr)
BR (1) BR112019001768A2 (fr)
CA (1) CA3031537A1 (fr)
CL (1) CL2019000248A1 (fr)
CO (1) CO2019000945A2 (fr)
EA (1) EA201990424A1 (fr)
IL (1) IL264514B (fr)
MX (1) MX2019001319A (fr)
PE (1) PE20190503A1 (fr)
PH (1) PH12019500202A1 (fr)
SG (2) SG11201900443VA (fr)
WO (1) WO2018026779A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10150769B2 (en) 2016-08-01 2018-12-11 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
CN109608460A (zh) * 2018-12-17 2019-04-12 上海合全药业股份有限公司 一种1,10-二氧亚基-2,7-二氮杂螺[4.5]癸烷-7-甲酸叔丁酯的合成方法
WO2019152687A1 (fr) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactame modulateur des récepteurs nmda et leurs utilisations
US10441571B2 (en) 2013-01-29 2019-10-15 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10906913B2 (en) 2008-09-18 2021-02-02 Northwestern University NMDA receptor modulators and uses thereof
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10961189B2 (en) 2016-08-01 2021-03-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525860A (ja) * 2020-05-12 2023-06-19 ベイジン・グレートウェイ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド Ｎｍｄａ受容体の活性を調節する化合物、その医薬組成物及び使用
CN114591326B (zh) * 2022-02-28 2024-02-27 上海筛杰生物医药有限公司 Cct-251921的中间体及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120800A1 (fr) * 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un récepteur nmda et leurs utilisations
WO2014120789A1 (fr) * 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un récepteur nmda et leurs utilisations
WO2014120786A1 (fr) * 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un récepteur nmda et leurs utilisations

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (fr) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthèse de bêta-lactame
CA1305177C (fr) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxypropylglycine et procede pour sa production
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (fr) 1988-07-25 1990-03-28 Glaxo Group Limited Dérivés de spirolactames
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (fr) 1990-10-30 2000-06-06 Shuichi Kasai Preparation antiinflammatoire sous forme de gel
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
WO1997046578A1 (fr) 1996-06-07 1997-12-11 Zeneca Limited Derives de peptides
AU3972797A (en) 1996-08-02 1998-02-25 Zymogenetics Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000027790A1 (fr) 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Composes a base de mutiline
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
US6521414B2 (en) 2000-02-01 2003-02-18 Agy Therapeutics, Inc. Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1
JP2001261679A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
WO2001096606A2 (fr) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification de genes et de composes pour le traitement du cancer
EP1296999A2 (fr) 2000-06-22 2003-04-02 NYXIS NeuroTherapies, Inc. Peptides neuroactifs servant a traiter l'hypoxie et des etats apparentes
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (fr) 2000-09-06 2003-12-10 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement des accidents cerebrovasculaires, contenant un facteur inhibitant la neutrophile et un antagoniste selectif du NMDA-NR2B
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU2002236608A1 (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
AU2002248553A1 (en) 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (fr) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Procede d'identification d'un agent lie au nmda
NZ537214A (en) 2002-07-05 2007-08-31 Targacept Inc N-Aryl diazaspiracyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2004232939A1 (en) 2003-04-17 2004-11-04 Merck Sharp & Dohme Corp. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
EP1776362A1 (fr) 2003-07-18 2007-04-25 Virochem Pharma Inc. Composes spiro et procedes pour moduler une activite de recepteur de chimiokime
US7544478B2 (en) 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
WO2005020973A2 (fr) 2003-08-29 2005-03-10 The University Of Houston System Compositions a activite antimycobacterienne comprenant un hydroxamate ou un hydroxamate et une hydroxylamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005047286A1 (fr) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. Compose spiranique heterocyclique
BRPI0418375A (pt) * 2004-01-08 2007-05-22 Hoffmann La Roche derivados de diaza-espiropiperidina
JP2008510711A (ja) * 2004-08-20 2008-04-10 ターガセプト，インコーポレイテッド 嗜癖治療におけるｎ−アリールジアザスピラ環状化合物の使用
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
CN101090902B (zh) * 2004-10-13 2013-05-29 默沙东公司 Cgrp受体拮抗剂
EP2431042B1 (fr) 2005-03-24 2013-06-26 Emory University Procédés pour le traitement des blessures du système nerveux central via un protocole d'administration biseauté
EP1945691A2 (fr) 2005-08-26 2008-07-23 Wisconsin Alumni Research Foundation Poly-beta-peptides a partir de monomeres de beta-lactame fonctionnalises ainsi que compositions antibacteriennes contenant ceux-ci
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008033464A2 (fr) 2006-09-15 2008-03-20 Schering Corporation Dérivés d'azétidinone et procédés d'utilisation de ceux-ci
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101675041A (zh) 2007-03-20 2010-03-17 沃泰克斯药物股份有限公司 用作激酶抑制剂的氨基嘧啶类化合物
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009039390A2 (fr) 2007-09-20 2009-03-26 Naurex Inc. Développement de procédés thérapeutiques à base de glycobiologie pour le traitement de tumeurs cérébrales
WO2009105718A1 (fr) 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Modifications génétiques associées à l'autisme et au phénotype autistique et procédés d'utilisation de celles-ci pour le diagnostic et le traitement de l'autisme
BRPI0914687A2 (pt) 2008-06-24 2015-10-20 Intervet Int Bv preparação veterinária por derramamento, métodos para tratar condições inflamatórias e para administrar a preparação veterinária por derramamento, e, uso da preparação veterinária por derramamento
EP2313394A1 (fr) 2008-06-27 2011-04-27 NeuroSearch A/S Nouveaux dérivés de la pipéridine à substitution par un tétraméthyle et leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs de monoamine
CA2732091A1 (fr) 2008-08-07 2010-02-11 F. Hoffmann-La Roche Ag Procede pour la preparation d'un macrocycle
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
WO2010065709A2 (fr) 2008-12-03 2010-06-10 Amin Khan Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2985032T3 (pl) 2009-10-05 2019-07-31 Northwestern University Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
EP2516439B1 (fr) 2009-12-21 2014-01-22 Novartis AG Diaza-spiro[5.5]undécanes en tant qu'antagonistes de récepteurs d'orexine
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN102933226A (zh) 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
GB201007789D0 (en) * 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
CN102267995A (zh) 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA2828219A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composes et compositions en tant qu'inhibiteurs de trk
HUE036408T2 (hu) * 2011-03-14 2018-07-30 Boehringer Ingelheim Int A leukotrién-termelés benzodioxán inhibitorai
KR20140043078A (ko) 2011-04-27 2014-04-08 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US9293690B2 (en) 2011-06-27 2016-03-22 Koninklijke Philips N.V. Ultrasound transducer assembly and method of manufacturing the same
CA2842647A1 (fr) 2011-07-18 2013-01-24 The Governors Of The University Of Alberta Catalyseurs et procedes destines a l'hydrogenation d'amides
PL3686194T3 (pl) 2011-07-27 2022-01-17 Astrazeneca Ab Związki 2-(2,4,5-podstawione-anilino)pirymidynowe
EP2796451B1 (fr) 2011-12-20 2018-08-01 Wei Qian Dérivé hétérocyclique de quinazoline substitué par un amido-alkyloxy et son utilisation
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CN102936216B (zh) 2012-12-05 2015-03-04 南京药石药物研发有限公司 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
CN105408336B (zh) 2013-01-29 2018-06-26 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA2898861C (fr) 2013-01-29 2021-07-20 Naurex, Inc. Modulateurs spirolactames d'un recepteur nmda et leurs utilisations
CN103171641B (zh) 2013-03-19 2015-07-15 浙江大学 具备轮动功能的弹跳机器人
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
GB2528480A (en) 2014-07-23 2016-01-27 Givaudan Sa Improvements in or relating to organic compounds
GB201416346D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
CA3024606C (fr) 2016-05-19 2019-09-03 Aptinyx Inc. Modulateurs de recepteurs nmda de spiro-lactame et utilisations associees
WO2017201285A1 (fr) 2016-05-19 2017-11-23 Aptinyx Inc. Modulateurs spirolactames des récepteurs nmda et leurs utilisations
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
WO2018026763A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations
CA3031539C (fr) 2016-08-01 2023-11-28 Aptinyx Inc. Modulateurs spirolactames des recepteurs nmda et leurs utilisations
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
EP3490990B1 (fr) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Modulateurs nmda a base de spirolactams et leur methode d'utilisation
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
SG11202007251XA (en) 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
US20210139489A1 (en) 2019-11-11 2021-05-13 Aptinyx Inc. Methods of treating painful diabetic peripheral neuropathy
US20210308101A1 (en) 2019-11-11 2021-10-07 Aptinyx Inc. Methods of treating fibromyalgia
KR20220110251A (ko) 2019-12-04 2022-08-05 앱티닉스 인크. 신경변성 질환과 연관된 인지 장애를 치료하는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120800A1 (fr) * 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un récepteur nmda et leurs utilisations
WO2014120789A1 (fr) * 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un récepteur nmda et leurs utilisations
WO2014120786A1 (fr) * 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un récepteur nmda et leurs utilisations

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BURGDORF ET AL.: "Positive emotional learning is regulated in the medial prefrontal cortex by GluN2B-containing NMDA receptors", NEUROSCIENCE, vol. 192, 2011, pages 515 - 523, XP028279417, DOI: doi:10.1016/j.neuroscience.2011.05.001
BURGDORF ET AL.: "The effect of selective breeding for differential rates of 50-kHz ultrasonic vocalizations on emotional behavior in rats", DEVEL. PSYCHOBIOL., vol. 51, 2009, pages 34 - 46
BURGDORF ET AL.: "The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus", NEUROSCIENCE, vol. 308, 2015, pages 202 - 211, XP029289248, DOI: doi:10.1016/j.neuroscience.2015.09.004
CARREIRA; KVAERNO: "Classics in Stereoselective Synthesis", 2009, WILEY-VCH: WEINHEIM
COLLINGRIDGE ET AL.: "The NMDA Receptor", 1994, OXFORD UNIVERSITY PRESS
FOSTER ET AL., NATURE, vol. 329, 1987, pages 395 - 396
MAYER ET AL., TRENDS IN PHARMACOL. SCI., vol. 11, 1990, pages 254 - 260
MOSKAL ET AL.: "GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator", NEUROPHARMACOLOGY, vol. 49, 2005, pages 1077 - 87, XP026192890, DOI: doi:10.1016/j.neuropharm.2005.06.006
RAUTIO, KUMPULAINEN ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 7, 2008, pages 255
SIMPLFCIO ET AL., MOLECULES, vol. 13, 2008, pages 519

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906913B2 (en) 2008-09-18 2021-02-02 Northwestern University NMDA receptor modulators and uses thereof
US10441572B2 (en) 2013-01-29 2019-10-15 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11077094B2 (en) 2013-01-29 2021-08-03 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10441571B2 (en) 2013-01-29 2019-10-15 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10961189B2 (en) 2016-08-01 2021-03-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11530223B2 (en) 2016-08-01 2022-12-20 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10150769B2 (en) 2016-08-01 2018-12-11 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
US11512051B2 (en) 2016-08-01 2022-11-29 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11427585B2 (en) 2016-08-01 2022-08-30 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
US11370790B2 (en) 2016-08-01 2022-06-28 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
US11376250B2 (en) 2016-08-01 2022-07-05 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN112204031A (zh) * 2018-01-31 2021-01-08 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2019152687A1 (fr) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactame modulateur des récepteurs nmda et leurs utilisations
US11578072B2 (en) * 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN109608460A (zh) * 2018-12-17 2019-04-12 上海合全药业股份有限公司 一种1,10-二氧亚基-2,7-二氮杂螺[4.5]癸烷-7-甲酸叔丁酯的合成方法

Also Published As

Publication number Publication date
IL264514A (en) 2019-02-28
AU2021240150A1 (en) 2021-10-28
IL264514B (en) 2021-09-30
KR20190033595A (ko) 2019-03-29
KR102465758B1 (ko) 2022-11-09
PH12019500202A1 (en) 2019-07-29
US20230312591A1 (en) 2023-10-05
CL2019000248A1 (es) 2019-06-21
EP3490992B1 (fr) 2023-03-22
MX2019001319A (es) 2019-07-04
CA3031537A1 (fr) 2018-02-08
US11530223B2 (en) 2022-12-20
CN109937204B (zh) 2022-11-25
BR112019001768A2 (pt) 2019-06-11
SG11201900443VA (en) 2019-02-27
SG10202101055VA (en) 2021-03-30
JP2019527233A (ja) 2019-09-26
PE20190503A1 (es) 2019-04-10
CN109937204A (zh) 2019-06-25
CO2019000945A2 (es) 2019-02-08
EA201990424A1 (ru) 2019-08-30
US11299495B2 (en) 2022-04-12
US20190177334A1 (en) 2019-06-13
AU2017306152A1 (en) 2019-01-31
JP7448766B2 (ja) 2024-03-13
EP3490992A1 (fr) 2019-06-05
US20220220119A1 (en) 2022-07-14
JP2022120019A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
US11530223B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
US11427585B2 (en) Spiro-lactam NMDA modulators and methods of using same
US11376250B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306136B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
WO2019152685A1 (fr) Spiro-lactame modulateur des récepteurs nmda et leurs procédés d'utilisation
WO2019152688A1 (fr) Spiro-lactame modulateur de récepteurs nmda et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17751544

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3031537

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019505213

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2017306152

Country of ref document: AU

Date of ref document: 20170801

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019001768

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197005666

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017751544

Country of ref document: EP

Effective date: 20190301

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112019001768

Country of ref document: BR

Free format text: APRESENTAR O RELATORIO DESCRITIVO.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: 112019001768

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.5 NA RPI NO 2522 DE 07/05/2019 POR TER SIDO INDEVIDA.

ENP Entry into the national phase

Ref document number: 112019001768

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190129